Industry News

Oct 24, 2018
By Pharmaceutical Technology Editors
The agency has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza.
Oct 23, 2018
By Pharmaceutical Technology Editors
Promise Pharmacy recalls one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3mL vials due to particulates in the solution.
Oct 23, 2018
By Pharmaceutical Technology Editors
Takhzyro (lanadelumab) is the first monoclonal antibody therapy approved for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Oct 23, 2018
By Pharmaceutical Technology Editors
The agency, in partnership with international regulatory and law enforcement agencies, cracked down on 465 websites marketing illegal opioids and other drugs claiming to treat conditions such as cancer and HIV.
Oct 23, 2018
Pharmaceutical Technology's In the Lab eNewsletter
By Pharmaceutical Technology Editors
Dr. C. Frank Bennett has been announced as a recipient of the Breakthrough Prize in Life Sciences in recognition of his contribution to the discovery and development of the first drug approved for the treatment of spinal muscular atrophy.
Oct 19, 2018
Pharmaceutical Technology
To achieve a more dynamic marketplace, FDA is issuing guidance documents and targeted advisories to support R&D on complex generics and combination products.
Oct 19, 2018
By Pharmaceutical Technology Editors
The recommended drugs include one biosimilar, two orphan medicines, and three extensions of therapeutic indications.
Oct 18, 2018
The US Department of Health and Human Services has published its proposed rule on the disclosure of drug prices, just in time for the November mid-term elections.
Oct 16, 2018
By Pharmaceutical Technology Editors
The new guidance, Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings Guidance for Industry, discusses the planning of pre-IND meetings with FDA and sponsors.
Oct 16, 2018
By Pharmaceutical Technology Editors
According to CPhI’s annual report, the therapeutic antibody drug conjugates (ADC) market is expected to reach $4 billion by 2023.
native1_300x100
lorem ipsum